Medicament for treatment cancer
A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.
1. A method of treating breast cancer, which is a breast cancer in which HER2 is highly expressed, comprising administering a first composition including an effective amount of amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof and a second composition including an effective amount of trastuzumab.
2. The method according to claim 1 , comprising administering amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof at 0.5-3.0 mg/kg/day and administering trastuzumab at 0.1-4.5 mg/kg/day.
3. The method according to claim 2 , comprising administering amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof on successive three days in every three weeks, while administering trastuzumab every one week.
4. The method according to claim 1 , comprising administering amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof at 1.5-9.0 mg/kg/day and administering trastuzumab at 0.1-4.5 mg/kg/day.
5. The method according to claim 4 , comprising administering amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof every three weeks, while administering trastuzumab every one week.
6. The method according to claim 2 , wherein a dosage ratio of amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1-8:1 at one week after initiating the administration of both agents.
7. The method according to claim 3 , wherein a dosage ratio of amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1-8:1 at one week after initiating the administration of both agents.
8. The method according to claim 4 , wherein a dosage ratio of amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1-8:1 at one week after initiating the administration of both agents.
9. The method according to claim 5 , wherein a dosage ratio of amrubicin, amrubicinol, or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1-8:1 at one week after initiating the administration of both agents.